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Introduction
Steroids, either prednisone or dexamethasone, are essential drugs in the remission induction phase of childhood acute lymphoblastic [1] [2] [3] leukemia (ALL) treatment based on their activity against lymphoblasts. In vitro studies and clinical trials showed that dexamethasone is superior 4, 5 to prednisone in killing lymphoblasts, and in lowering the incidence of central nervous system (CNS) involvement due to higher concentration of free drug and greater capacity to penetrate the blood-brain barrier than [6] [7] [8] prednisone. Randomized trials in Western countries have shown that dexamethasone results in higher event-free survival (EFS) and fewer CNS relapses than prednisolone. However, this might be at the expense of higher toxic deaths even though (due to low numbers) this effect did not 8, 9 reach significance. A systematic review and meta-analysis published after our randomization procedure confirmed the findings of significantly lower CNS relapse and reduced events in the dexamethasone group 10 compared with the prednisone group. However, drug-related toxicity was significantly higher with dexamethasone than with prednisone 8,11 12 13 in terms of induction death, risk of fractures, gastritis and weight gain. With the much higher toxic death rates (17% -23%) reported in low-income [14] [15] [16] [17] countries, the toxicity of dexamethasone might prove to be excessive. Since 1992, the Indonesian protocols for childhood ALL were 16 dexamethasone based rather than prednisone based. However, because doubts arose about the toxicity of dexamethasone, we conducted a prospective randomized study to evaluate whether the type of steroid used might influence the outcome in our local setting. The problems frequently encountered in Indonesia and other low-income countries (e.g. treatment abandonment, toxic death, resistant disease and relapse) were evaluated.
Methods

Patients
This prospective study was conducted in the Pediatric Cancer Unit (PCU) of Dr. Sardjito Hospital, Yogyakarta, Indonesia. Childhood ALL patients newly diagnosed during the period from May 22, 2006 (standard risk, SR) or May 1, 2009 (high risk, HR) until December 28, 2011 were enrolled in this study. The study was started first in SR patients expanded to include HR patients. All patients were treated according to the Indonesia-ALL-2006 protocol. Diagnosis of ALL was primarily based on morphological assessment using the French-American-British (FAB) classification and was supported by immunophenotype examination. Patients with FAB-L3 morphology or mature B-ALL were excluded. The inclusion criteria were: age 0 -14 completed years, newly diagnosed, and no prior treatment with steroids or chemotherapy. Informed consent was signed by parents or guardians. Criteria for SR were age 1 -10 years, WBC less than 50,000/µl, no mediastinal mass, no CNS involvement, and B-cell lineage as well as a blast count of less than 1000/µl after the 1-week pre-phase treatment. All other patients were classified as HR.
Random allocation into the dexamethasone or prednisone arm was done using a computer program after diagnosis and parental approval. The observation period ended March 23, 2012 . The characteristics of the patients are shown in Table 1 .
Treatment Protocol
The Indonesia-ALL-2006 protocol was the successor of the first generation of Indonesian national protocols for childhood ALL treatment, 18 namely the WK-ALL-2000 protocol. The WK-ALL-2000 protocol was adapted from the Dutch ALL-VI protocol and was based on 3-drug 19 induction with dexamethasone as the steroid. In the Indonesia-ALL-2006 protocol (Figure 1 ), the induction consisted of 4 drugs including 4 doses of 2 daunorubicin (30 mg/m ) for SR and HR patients. In the case that daunorubicin was not available it was replaced by doxorubicin at a dose 2 of 20 mg/m . After induction patients received a consolidation and maintenance treatment. A re-induction course was inserted after the consolidation treatment in HR patients. Patients in the dexamethasone 2 arm received prednisone 60 mg/m /day during one week pre-phase, 2 then dexamethasone 4 mg/m /day during induction, and in blocks during 2 maintenance for SR patients; or dexamethasone 6 mg/m /day during one week pre-phase, as well as in induction, re-induction and maintenance treatment blocks for HR patients. Patients in the prednisone arm received 2 2 prednisone 60 mg/m /day during pre-phase, then 40 mg/m /day during induction and maintenance treatment blocks (SR patients) or prednisone and later 2 40 mg/m /day during pre-phase, induction, re-induction and in maintenance treatment blocks (HR patients). At the end of the pre-phase SR patients with a peripheral lymphoblast count of more than 1000/µl were switched to the HR protocol. 
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Outcomes and statistical analysis
The aim of this study was to compare the efficacy of dexamethasone versus prednisone in the Indonesia-ALL-2006 treatment protocol. The outcomes were death rate, abandonment rate and leukemic events (resistant disease and relapse). We calculated EFS from the date at start of treatment to the date of an event which occurred first: death, abandonment, resistant disease or relapse. LFS was calculated from the date at start treatment to the date of resistant disease confirmation at the end of induction, or first relapse after achievement of complete remission (CR). The overall survival (OS) was calculated from the date at start of treatment to the date of death by any cause. CR was determined at the end of induction treatment and defined as no detectable lymphoblasts in peripheral blood or cerebrospinal fluid and less than 5% lymphoblasts in active hemopoietic marrow, and no physical signs of infiltrative leukemic cells anywhere. Patients who were alive without any event were censored at the date of analysis on March 23, 2012. Patients who abandoned treatment whilst in CR, or who relapsed, were considered failures at the time of their withdrawal or relapse. All families of patients were personally contacted on the date of analysis to check the patient's status.
The EFS, LFS and OS curves were estimated using the KaplanMeier method and compared using the log-rank test. A P-value less than 0.05 was used as level for statistical significance. The data were analyzed using the SPSS version 13.0.
Results
During the study period, 291 patients with ALL were admitted to Dr. Sardjito Hospital, Yogyakarta. Of these, 62 did not meet the inclusion criteria due to: refusal of treatment (23), previous treatment with steroids or ALL treatment (9), death before treatment started (8), L3 morphology (8), age at diagnosis 15 years or more (5), mixed leukemia (4), moved to other treatment protocols (4), or to another hospital (1). The remaining 196 patients consisted of 134 SR and 62 HR patients. Immunophenotyping was done in 84 patients and confirmed as T-cell (6) or precursor B-cell ALL (75), while 3 patients were characterized as mature B-cell lineage ALL and thus excluded from this study. For 112 patients no data on immunophenotype were available since the examination was not yet developed at the time of diagnosis, or due to technical problems such as lack of specimen, clotted specimen or inconclusive results. At the time of analysis all patients had finished induction treatment or experienced induction failure. The median follow-up of patients in remission since entering treatment until the time of analysis was 22 (range: 3 -60) months in the dexamethasone arm and 26 (range: 4 -67) months in the prednisone arm (P=0.25). Of the 196 patients enrolled in this study, 102 (52%) were randomized to the dexamethasone arm and 94 (48%) to the prednisone arm. The characteristics at diagnosis such as risk group, age, sex, WBC group and immunophenotype were equally distributed between the dexamethasone arm and prednisone arm ( Table 1 ). The median age was 4.0 years (range: 2 months -14 years) in the dexamethasone arm and 4.0 years (range: 5 months -14 years) in the prednisone arm.
Of the 196 patients, 141 (72.4%) patients achieved CR: 71/102 (69.6%) patients in the dexamethasone arm and 71/94 (75.5%) in the prednisone arm (P=0.35) ( Table 2 ). The clinical outcomes in the overall ALL patient group showed no significant differences between the dexamethasone and prednisone arms in terms of abandonment of treatment (24.5% vs. 25.5%, P=0.91), death (17.7% vs. 14.9, P=0.54), leukemic events (13.7% vs. 11.7%, P=0.59) and continuous CR achievement (44.1% vs. 47.9%, P=0.60). In both arms, all relapses were hematological relapses and 76% occurred during treatment, mostly in maintenance treatment (65%). The median time to relapse after achievement of CR was 16 (range: 10 -30) months in the dexamethasone arm and 22 (range: 2 -29) months in the prednisone arm (P=0.88). No secondary malignancy was found during this study.
Separate analysis of SR patients revealed a trend for a higher death rate during induction in the dexamethasone compared to the prednisone arm (16.2% vs. 6.1%, P=0.06) with equal abandonment and leukemic events in both arms (Table 3 ). In HR patients the dexamethasone versus the prednisone arms showed no significant difference in terms of treatment abandonment, death and leukemic events either during induction or overall ( Table 4) .
The 3-year EFS in the dexamethasone arm was 31.5% ± 6.6% versus 41.5% ± 5.9% (P=0.51) in the prednisone arm (Figure 2) . The 3-year LFS in the dexamethasone arm versus the prednisone arm was 63.7 ± 9.3% versus 74.5 ± 7.6% (P=0.47) (Figure 3 ) and the 3-year OS in the dexamethasone arm versus the prednisone arm was 49.5 ± 7.7% versus 69.3 ± 6.1% (P=0.09) (Figure 4 ). 
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Discussion
This study compared the efficacy of dexamethasone versus prednisone in newly diagnosed childhood ALL patients treated in a low-income setting in Indonesia. The Indonesian protocols have utilized dexamethasone as steroid for more than 15 years based on the evidence of a lower incidence of meningeal leukemia in childhood ALL patients 7 treated with dexamethasone instead of prednisone and the high cure rate 19 achieved with the dexamethasone-based Dutch ALL-VI protocol. However, a UK randomized study showed that dexamethasone was also associated with more toxicities than prednisone, i.e. treatment-related death in the dexamethasone group was higher than in the prednisone 8 group (4.6% vs. 2.4%, P=ns). Considering that toxic death is much higher in Indonesia and other low-income countries compared with Western countries, the question arose whether dexamethasone might be too toxic in the Indonesian setting. The present study was conducted to address this question.
However, the outcomes in the overall ALL cohort showed no significant differences between the dexamethasone and the prednisone arms, including rates of treatment abandonment, death and leukemic events. In our setting, refusal or abandonment of treatment and toxic death during induction treatment or in remission were the major causes of treatment failure. These adverse events occurred in appreciably higher rates than in Western countries where abandonment is almost non-existent [20] [21] [22] [23] [24] and the death rate is reported to be 1 -5%. The high level of treatment refusal and abandonment, and toxic death rates, may represent problems [14] [15] [16] [17] [18] 25, 26 typically seen in low or medium-income countries that lead to inferior survival rates compared to Western studies. Studies in our PCU showed that abandonment of treatment is due to multi-factorial causes related to financial issues (i.e. occurring more often among poorer patients), difficulty with transportation to the hospital, experienced traumatic side-effects, socio-economic status, family perception of disease curability, and lack of professionalism of the health provider (including their attitude/communication skills in ensuring compliance with 16, [27] [28] [29] [30] [31] treatment of patients and parents).
Compared with children enrolled at the implementation of the Indonesian childhood ALL protocol during however, both events remain prominent in our daily practice. Many programs have been developed to overcome this problem, including the introduction of a structured parental education program, 32 improvement of access to medicine donation, development of human resources and PCU infrastructure, together with the issuing of a government health insurance program intended for poor people during 33 the last 8 years. 16 Compared with the previous study in our PCU, the toxic death rate has reduced from 23% (38/164) to 16% (32/196) ; however, the follow-up procedure between the former protocol and the current protocol differs considerably. The finding that the toxic death rate mostly occurred during induction treatment suggests the important role of supportive care for the life-threatening conditions during this phase. Our study on patients treated with the less intensive Indonesian WK-ALL-2000 protocol (1999 -2005) in our PCU had resulted in severe neutropenia during induction treatment with a median nadir of absolute neutrophil count (ANC) of 165 (range: 5 -25,480) cells/µl (data in press). It is generally assumed that lack of access to supportive care is the cause of the high toxic death rates in low-income countries. Separate analysis in the SR patients revealed that the dexamethasone arm tended to have a higher induction death rate (16.2%) than patients in the prednisone arm (6.1%; P=0.06). This result is in line with the UKMRC ALL97 study which also found a higher early death (less than 60 days) rate in the dexamethasone group than in the prednisolone group (1.8% vs. 0.7%, P=0.07); however, in that 8 study the absolute number was too low to achieve significance. A possible explanation for this could be a notable tendency towards higher septicemia and induction death in childhood ALL treated with CR rates of about 95% with a 5-year overall EFS of 56% -83%. The Dutch protocol ALL-6 and ALL-9, both dexamethasone-based protocols with 3-drug induction for non-HR patients, have generated an overall 5-year 37, 38 EFS of 82% and 84%, respectively. This outcome might be related to the better supportive care in Western countries, but perhaps also to the less toxicity in the 3-drug induction protocol thus less induction deaths. In the present study, further analysis in the HR group showed no significantly different outcomes between patients in the dexamethasone and the prednisone arms.
As reported by studies in Western countries, dexamethasone [7] [8] [9] is superior to prednisone in preventing relapse, particularly in the CNS. This finding could not be confirmed in our study since all relapses in both arms were hematological ones. In our PCU, lack of experience in diagnosis of CNS relapse may have obscured the finding of CNS relapses. In addition, a short follow-up period may explain why most relapse occurred during maintenance treatment. In terms of protocol efficacy, in the present study the EFS, LFS, and OS showed no significant difference between the dexamethasone and the prednisone arms. However, the prednisone arm showed a trend to have a higher probability of OS at 4 years (69.3 ± 6.1% vs. 44.0 ± 8.6%, P=0.09) than the dexamethasone arm. The non-superior outcome of dexamethasone arm could be partly explained by the administration of a less effective dose of dexamethasone 2 in SR patients. The CCG-1922 study using prednisone 40 mg/m 2 vs. dexamethasone 6 mg/m during induction showed significantly better 39 10 EFS in the dexamethasone arm. A meta-analysis of 8 Western studies showed a significant reduction of event rate (death from any cause, refractory or relapsed leukemia, or second malignancy) in the dexamethasone arm than in the prednisone arm at a ratio of prednisone and dexamethasone of less than 7. The event rate was the same in prednisone and dexamethasone when the ratio was 7 or more. In terms of preventing relapse, dexamethasone significantly reduced CNS relapse compared with prednisone; this applied to a ratio of prednisone and dexamethasone of both less than 7 and 7 or more. The meta-analysis concludes that dexamethasone is more efficacious than prednisone USA and the UK showed that SR in induction treatment for childhood ALL. However, dexamethasone is also more toxic. The Indonesian childhood ALL protocol for HR used 2 2 40 mg/m for prednisone and 6 mg/m for dexamethasone, whereas the SR 2 group used the lower dose of dexamethasone (40 mg/m for prednisone 2 and 4 mg/m for dexamethasone). Nevertheless, the induction deaths in the SR dexamethasone group (16.2%) were almost three-fold higher than in the prednisone arm (6.1%; P=0.06) ( Table 2 ). Although there is no consensus on dose conversion between dexamethasone and prednisone, the typical conversion between prednisone and dexamethasone is 1 mg dexamethasone equivalent to 7 mg prednisone, or dexamethasone 6 mg as 'equivalent' to prednisone 40 mg (as used in many studies). It is noteworthy that the treatment outcome of childhood ALL patients in Indonesia has advanced during the last decade, with increasing 3-year EFS from about 20% in the WK-ALL-2000 protocol to about 37% in the Indonesia-ALL-2006 protocol. Although this achievement can in no way be compared to studies in Western countries that report cure rates of 40 over 80%, our achievement shows that childhood ALL can be treated successfully in a low-income situation such as in Indonesia. This progress illustrates the benefit of our twinning program with the VU University 18 Medical Center (Amsterdam, the Netherlands), which generated research projects and significantly improved our knowledge related to treating childhood cancer.
In an attempt to obtain better outcomes from the Indonesia-ALL-2006 protocol, we recommend to skip the anthracyclines from induction treatment in the SR patients and to continue the randomization of dexamethasone and prednisone during a 3-drug induction for SR patients in an Indonesian multicenter study. Further study may 2 2 randomize the dose of 40 or 60 mg/m prednisone versus 6 mg/m dexamethasone. Our study supports the opinion advocated by 41 Hunger et al. that developing a protocol in countries with poor supportive care, and where few children are currently being cured, should be performed with extreme caution with regard to potential toxic and drug-related life-threatening complications.
